Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Sailer

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
British Journal of Pharmacology|February 7, 2026
Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthmaSaskia Carstensen-Aurèche, Tobias Litzenburger, Dorothy De Sousa, et al.
British Journal of Clinical Pharmacology|March 10, 2025
Exposure-tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selectionIda Neldemo, Kamunkhwala Gausi, Céline Sarr, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
British Journal of Pharmacology|February 7, 2026
Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthmaSaskia Carstensen-Aurèche, Tobias Litzenburger, Dorothy De Sousa, et al.
British Journal of Clinical Pharmacology|March 10, 2025
Exposure-tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selectionIda Neldemo, Kamunkhwala Gausi, Céline Sarr, et al.
Pageof 2